Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evenamide add-on fixed-dose pilot study in treatment-resistant schizophrenia
2020-000437-41Phase 2Completed
- Sponsor
- NeurOn Pharmaceuticals
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of evenamide in schizophrenia (3 arms), sponsored by NeurOn Pharmaceuticals. Primary endpoints: Safety and Tolerability. Started Oct 2020; status: completed.
02
Drugs
evenamide
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2020-000437-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000437-41.